Navigation Links
Largest National U.S. Healthcare Facility MRSA Study Reveals,Infection Rates Eight Times Greater Than Previous Estimates

ents a grim picture," said William Jarvis, MD, principal investigator of the study and president and co-founder of Jason and Jarvis Associates, a private consulting firm in healthcare epidemiology. "The findings argue for immediate, aggressive efforts to detect and prevent transmission of MRSA. Because the true magnitude of the total MRSA burden in the U.S. healthcare population is unknown, our objective was to provide the first national estimate of MRSA in U.S. healthcare facilities."

The research indicated that once MRSA cases are identified, healthcare facilities employ recommended practices to prevent transmission of the organism, such as practicing barrier precautions (use of gloves and gowns), hand hygiene and isolating MRSA patients. 81 percent of patients in the study were not identified until they presented signs or symptoms of an active infection prompting doctors to order lab tests. This finding implies that a significant number of patients are potentially transmitting MRSA to healthcare workers and other patients before the bacteria are identified.

"Quite simply this survey is a wake up call for healthcare facilities to save lives by dedicating more resources to infection prevention and control because the transmission of MRSA is preventable," said Denise Murphy, president of APIC and Vice President of Safety and Quality, and Chief Patient Safety and Quality Officer at Barnes-Jewish Hospital at Washington University Medical Center in St. Louis. "Some healthcare facilities are aggressively addressing MRSA, but the scope of this public health threat demands commitment and participation from every hospital, at all levels of the facility. Hospitals should commit the resources to conduct a thorough risk assessment of patient populations and implement viable strategies to prevent MRSA and other antimicrobial-resistant infections. These measures could help prevent this epidemic from continuing to spiral upward and out of control."

APIC guid
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America
6. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
7. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
8. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
9. Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings
10. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
11. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
Post Your Comments:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 1WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 2WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 3Red Cross Offers the Trick to Safety this Halloween 60220 1Red Cross Offers the Trick to Safety this Halloween 60220 2Connectyx Announces the MedFlash Personal Health Manager 60218 1Connectyx Announces the MedFlash Personal Health Manager 60218 2Connectyx Announces the MedFlash Personal Health Manager 60218 3